Delivery Order SPE2DB24D2106-SPE2DB26FATWP
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $13,735.58 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose in 2-pen/mL formulation on August 25, 2025. This firm fixed-price delivery order, with an ultimate completion date of August 26, 2025, represents a pharmaceutical supply requirement with performance taking place in Conshohocken, Pennsylvania. The award was made without set-aside designation to DMS Pharmaceutical Group, a woman-owned small business...
- The Defense Logistics Agency awarded a $19,259.62 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose-2 pen/ml pharmaceutical products. The delivery order, issued on September 11, 2025, with an ultimate completion date of September 12, 2025, does not utilize a set-aside designation. Performance will be executed in Conshohocken, Pennsylvania. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park...
- The Defense Logistics Agency awarded a $8,935.09 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300mg dose in 2 pen/mL formulation on September 8, 2025, with an ultimate completion date of September 9, 2025. This award carries no set-aside designation and represents performance at the vendor's location in Conshohocken, Pennsylvania. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, is...
- On June 2, 2025, the Defense Logistics Agency awarded a firm fixed-price delivery order valued at $9,807.94 to DMS Pharmaceutical Group Inc. for the supply of Cosentyx (secukinumab) 300mg dose-2 pen/ml. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order with performance at its Conshohocken, Pennsylvania location. The award carries no set-aside designation, and the delivery order is scheduled for ultimate...
- The Defense Logistics Agency awarded a delivery order valued at $4,200.08 to DMS Pharmaceutical Group Inc. for Cosentyx (secukinumab) 300 mg pen 2 ml on August 25, 2025, with completion expected by August 26, 2025. This firm fixed-price delivery order represents a specific pharmaceutical requisition issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA under the SPE2DB program, valued at $499.999 billion and extending through November 2026. The award carries no...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Illinois, received a delivery order valued at $23.5K from the Defense Logistics Agency (DLA) on June 16, 2025, for Cosentyx (secukinumab) 300mg dose in 2-pen/mL format. This firm fixed-price delivery order, with an ultimate completion date of June 17, 2025, was awarded without set-aside designation and will be performed in Conshohocken, Pennsylvania. The award falls under DMS Pharmaceutical Group's...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $50,400.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cosentyx (secukinumab) 300 mg pre-filled pens. The award was made on September 18, 2025, with an ultimate completion date of September 19, 2025, and carries no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger single-award...
- On August 20, 2025, the Defense Logistics Agency awarded a delivery order valued at $10,461.10 to DMS Pharmaceutical Group Inc. for the supply of Cosentyx (secukinumab) 300 mg pen 2 mL injections. This firm fixed-price delivery order, which is expected to be completed by August 21, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA. The contract does not utilize a set-aside designation, and the pharmaceutical products will be...
- The Defense Logistics Agency awarded a $16.8K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cosentyx (secukinumab) 300 mg pen injections. The order, issued on July 25, 2025, with an ultimate completion date of July 28, 2025, represents a firm fixed-price delivery under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million and valid through November...
- The Defense Logistics Agency (DLA) awarded a $5,015.29 delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Cosentyx (secukinumab) 300mg dose injections. This firm fixed-price delivery order, awarded on September 16, 2025, with an ultimate completion date of September 17, 2025, represents a single-unit pharmaceutical procurement with no set-aside designation. The product will be delivered to...
- SPE2DB24D2106Indefinite Delivery Contract
- SPE2DB24D2106-SPE2DB26FATWPDelivery Order
The Defense Logistics Agency issued a firm fixed-price delivery order valued at $26,263.93 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Cosentyx (secukinumab) 300mg dose in 2-pen format. The award, issued on October 20, 2025, with an ultimate completion date of October 21, 2025, carries no set-aside designation, indicating the company competed in unrestricted federal procurement. Performance will occur at DMS Pharmaceutical Group's facility in Conshohocken, Pennsylvania. This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $499.999 billion acquisition strategy designed to ensure reliable pharmaceutical supply chains supporting military healthcare facilities worldwide. DMS Pharmaceutical Group, headquartered in Park Ridge, Illinois and registered in the System for Award Management since 2001, serves as a critical regional prime vendor contractor within the PPV-G GEN V framework. The company's extensive product portfolio encompasses branded and generic pharmaceuticals, biologics, vaccines, and medical consumables, with demonstrated capability across multiple therapeutic categories including specialty oncology treatments, immunosuppressants, and emergency medications. This delivery order for Cosentyx, an immunosuppressant biologic used in treating autoimmune conditions, reflects the company's established role in providing specialized pharmaceutical products to support Department of Defense medical operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.3k | 10/20/25 |